Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2019
Cash flows from operating activities:    
Net loss $ (41,952) $ (26,958,247)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation   9,785,083
Research and development expense - license acquired- CMU   1,046,965
Research and development expense - license acquired- Ohr   11,920,450
Change in fair value of warrant liabilities   492,889
Depreciation and amortization   128,372
Non-cash amortization on convertible notes discount   94,444
Non-cash interest expense on convertible notes   21,772
Changes in operating assets and liabilities (excluding the effects of acquisitions)    
Prepaid expenses and other current assets   (386,499)
Accounts payable 21,683 962,434
Accrued expenses 19,814 385,765
Long term prepaid insurance expense   (338,916)
Net Cash Used in Operating Activities (455) (2,845,488)
Cash flows from investing activities    
Purchase of laboratory and office equipment   (455,200)
Cash acquired in connection with Acquisition of Ohr   752,419
Payment of transaction costs for Acquisition of Ohr   (884,981)
Payment of transaction costs for licenses acquired- CMU   (43,463)
Cash paid for license acquired- CMU   (54,000)
Net cash used in investing activities   (685,225)
Cash flows from financing activities    
Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs 55 8,268,157
Proceeds from issuance of common stock in private placement financing, net of issuance costs   4,957,397
Proceeds from issuance of convertible notes 250,000 600,000
Payment for warrant redemption   (141,864)
Principal payment of financed insurance   (90,081)
Proceeds from issuance of common shares for services   1,474
Proceeds from prefunded warrant   10
Repurchase of common stock   (14)
Net cash provided by financing activities 250,055 13,595,079
Net increase in cash and cash equivalents 249,600 10,064,366
Cash and cash equivalents, beginning of period   249,600
Cash and cash equivalents, end of period 249,600 10,313,966
Supplemental disclosure of cash flow information:    
Cash paid for interest   3,177
Non-cash investing and financing activities:    
Issuance of common stock for research and development expense-licenses acquired - CMU   844,600
Issuance of common stock for conversion of debt   944,444
Issuance of common stock for conversion of accrued interest   21,772
Issuance of common stock for the cashless exercise of warrant   429,677
Insurance financed through note payable   213,000
Issuance of common stock and options for acquisition of Ohr   $ 11,776,927
Unpaid stock subscription $ 1